Menu

日本依普利酮降血压效果好吗

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

Is Japanese eplerenone effective in lowering blood pressure? Eplerenone is used for the treatment of essential hypertension and heart failure after myocardial infarction. Its antagonism to aldosterone is stronger than that of spironolactone, and it has extremely low affinity for androgen and progesterone receptors and has few adverse reactions. It has a positive therapeutic effect in the treatment of hypertension, heart failure and myocardial infarction, and is well tolerated. It is a good alternative to spironolactone. Patients should choose drugs based on their physical condition and disease stage.

The initial dose of eplerenone for the treatment of congestive heart failure is 25 mg orally once daily; increase to the target dose within four weeks as tolerated by the patient. The target dose is 50 mg orally once daily.

When treating adult patients with hypertension, eplerenone can be used alone or in combination with other antihypertensive drugs. It is administered orally. The initial dose is 50 mg, once a day; the maintenance dose is 50 mg, 1-2 times a day. The maximum dose is 100 mg/day and patients should not overdose. Typically, significant blood pressure lowering effects occur within four weeks of taking eplerenone. Patients whose blood pressure responds inadequately to the initial dose may be increased to 50 mg twice daily.

Studies have shown that for severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of eplerenone can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. Combined treatment with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve patients' quality of life and reduce mortality in severe heart failure and myocardial infarction.

The above is the introduction about (eplerenone), I hope it can help everyone. If patients have other questions about the drug (such as drug price, purchasing channels, etc.), they can consult the medical companion travel service.

Recommended related hot articles: /newsDetail/79922.html

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。